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Purpose: GSK3B and AKT1 genes have been implicated in the pathogenesis of a number of 
psychiatric and neurological disorders. Furthermore, their genetic variants are associated with 
response to antidepressant pharmacotherapy. As the evidence is still incomplete and inconsistent, 
continuing efforts to investigate the role of these two genes in the pathogenesis and treatment of 
brain disorders is necessary. The aim of our study was thus to evaluate the association of variants 
of these two genes with depressive disorders and drug treatment response.
Patients and methods: In the present study, 222 patients with a depressive disorder who under-
went pharmacological antidepressant treatment were divided into remitters and non-remitters 
following a 28-day course of pharmacotherapy. The association of a depressive disorder and 
remission rates with polymorphisms rs334558 in the GSK3B gene and rs1130214 and rs3730358 
in the AKT1 gene was evaluated with a chi-square test.
Results: Neither of the studied genetic variants was associated with a depressive disorder. 
Furthermore, frequencies of alleles and genotypes for rs1130214 and rs3730358 were not 
different in the groups of remitters and non-remitters. However, the activating allele T of the 
functional polymorphism rs334558 was significantly associated with remission, when all types 
of antidepressant drugs were included. This association continued as a trend when only patients 
taking selective serotonin reuptake inhibitors were considered.
Conclusion: The present study provides support that the functional polymorphism rs334558 
of GSK3B may play a role as a useful genetic and pharmacogenetic biomarker in the framework 
of personalized medicine approach.
Keywords: depressive disorder, association study, AKT1, GSK3B, genetic biomarker
Introduction
Depressive disorders are the third leading cause of disability worldwide, according to 
a 2015 report.1 The phenotype is complex, indicating the existence of numerous types 
and subtypes,2 as are genetic factors contributing to these disorders.3–5 Inheritance of 
one type, major depressive disorder (MDD), is only 30–40%, as was shown by twin 
studies.6,7 Therefore, environmental factors, translated as epigenetics, must play a sub-
stantial role in the etiology.8,9 Despite the apparent difficulties in the study of genetics 
of depressive disorders, there have been some breakthroughs in the last several years.4 
An apparent reason that replicable results in genetic studies of depressive disorders 
have been difficult to achieve is that the patients constitute a very heterogeneous group 
and the most appropriate approach would be to view depressive disorders from the 
angle of personalized medicine.10–19 An example of personalized approach is Research 
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Domain Criteria that take account of molecular factors in 
the pathogenesis of mental illnesses.20–22 This approach is 
particularly relevant, given the fact that, for example, MDD 
is pharmacotherapy-resistant in 30–40% of cases.23 Indeed, 
without understanding the precise etiopathological mecha-
nisms in different groups of patients, it will not be possible 
to treat these disorders efficiently.
An important volume of pharmacogenetic studies of 
depressive disorders exists, including genome-wide associa-
tion studies and case–control association studies using candi-
date genes24–28 (pharmacoepigenetics of depressive disorders 
is also a developing field29). One of the candidate genes used 
in pharmacogenetic studies in psychiatry is AKT1, a gene 
implicated in the pathogenesis of psychiatric disorders and 
response to medication via the AKT/GSK3 pathway.28,30–34 
Single nucleotide polymorphisms (SNPs) rs1130214 and 
rs3730358 in this gene were investigated in the present 
study because of association of the TC haplotype with lower 
protein levels of AKT1, which suggests impaired mRNA 
expression or processing.34 In addition, SNP rs3730358 was 
found to be associated with late-onset depression.35 Another 
candidate gene is GSK3B, one of the major regulators of 
multiple molecular pathways, including WNT36,37 and AKT/
GSK3 pathways.30,32 In fact, implication of GSK3B and of 
its pathways in psychiatric disorders has been extensively 
investigated.32–34,38–48 This gene is directly or indirectly 
inhibited by antipsychotics, lithium, and antidepressants.30,31 
The variant rs334558, found in the promoter of GSK3B, 
is known to be functional, as it determines the expression 
level of GSK3B, possibly by regulating the transcription 
factor binding to the promoter.49 In particular, the allele T is 
associated with a 1.4-fold increased transcriptional strength, 
compared to the ancestral allele C, apparently because the 
nucleotide T  creates a new binding site at the promoter for 
the transcription factor AP4.
In the present study, we report the association of remission 
following pharmacological antidepressant treatment with 




The study was carried out in accordance with The Code of 
Ethics of the World Medical Association (Declaration of 
Helsinki 1975, revised in Fortaleza, Brazil, 2013) for experi-
ments involving humans. After approval of the study protocol 
by the Local Bioethics Committee of the Mental Health 
Research Institute in Tomsk, Russia (Siberian region), 222 
patients were recruited from an inpatient facility of the same 
institute. One hundred and twenty-seven control subjects 
without psychiatric disorders were also recruited into the 
study. Only subjects of European ancestry were considered. 
All subjects gave written informed consent after a proper 
explanation of the prospective study.
In particular, we included patients with a depressive dis-
order, determined using the following diagnostic criteria of 
the International Statistical Classification of Diseases and 
Related Health Problems, 10th Revision (ICD-10): depres-
sive episode (ICD-10: F32, 44.4%), recurrent depressive 
disorder (ICD-10: F33, 34.4%), bipolar disorder (ICD-10: 
F31, 15.3%), and dysthymia (ICD-10: F34.1, 2.9%). The 
available demographic data comprised age (18–70 years 
or 49.93 ± 10.76 years), gender (177 women and 45 men), 
education (university 43.8%, professional college 44.4%, 
secondary school 11.8%), employment (employed 68.4%, 
unemployed or retired 31.6%), and marital status (married 
53.2%, widowed 19.3%, divorced 17%, single 10.5%).
Clinical and demographic data were initially recorded in 
hard-copy medical files by psychiatrists at the Department 
of Affective Disorders of the Mental Health Research Insti-
tute in Tomsk, and this work was supervised by Dr. German 
Simutkin. These collected data were then transferred to a 
digital file (an electronic database) and were extracted from 
it during our study.
During their follow-up in the clinic, patients were given 
several different groups of antidepressants: selective sero-
tonin reuptake inhibitors (SSRIs) (escitalopram, fluoxetine, 
paroxetine, fluvoxamine, sertraline, citalopram) (57.9% of 
patients), tricyclic antidepressants (clomipramine, pipofe-
zine) (20.0%), serotonin–norepinephrine reuptake inhibitors 
(duloxetine, venlafaxine) (7.1%), noradrenergic and spe-
cific serotonergic antidepressants (mirtazapine, mianserin) 
(2.7%), and agomelatine (12.3%). All antidepressants were 
used in recommended average therapeutic doses. The dura-
tion of treatment was not less than 28 days. For definition 
of remission, Hamilton Depression Rating scale 17 items 
(HDRS-17)50 was used. The evaluation was made on the 28th 
day of treatment. Remitters were identified if the HDRS-17 
scores were ≤7.
Genotyping
Evacuated blood collection tubes “Vacutainer” (Becton 
Dickinson, Franklin Lakes, NJ, USA) with EDTA as the 
anticoagulant were used. Extraction of DNA from whole 
venous blood was performed using the phenol–chloroform 
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GSK3B and remission in depression
using NanoDrop 8000 UV-Vis (ultraviolet-visible) spectro-
photometer (Thermo Fisher Scientific, Waltham, MA, USA).
SNPs rs334558 of the GSK3B gene and rs1130214 and 
rs3730358 of the AKT1 gene were genotyped by polymerase 
chain reaction (PCR) using the fluorogenic 5′-exonuclease 
TaqMan technology and the real-time PCR system “StepOne-
Plus” (Applied Biosystems, Foster City, CA, USA).
Statistical procedures
Statistical analyses were performed using SPSS software, V 
20.0 (IBM Corporation, Armonk, NY, USA) for Windows. 
Pearson’s chi-square test was used for the between-group 
comparison of genotypic and allelic frequencies at sig-
nificance level α = 0.05. Deviation from Hardy–Weinberg 
equilibrium of genotypic frequencies was also calculated 
with a chi-square test.
Results
Of the three SNPs tested, none were associated with depres-
sive disorders when genotypes and alleles were compared 
between cases and controls. Association was significant only 
for the SNP rs334558, constituted by alleles T and C, when 
the group of remitters was compared to non-remitters, for 
all pharmacological classes of medication taken together. 
Allele T was found to be associated with remission after 28 
days of treatment. In particular, genotypes and alleles were 
different between remitters and non-remitters, at p = 0.049 
and p = 0.015, respectively (odds ratio [OR] genotype T/T 
= 2.49, 95% CI: 0.98–6.30; OR allele T = 2.19, 95% confi-
dence interval [CI]: 1.01–4.75). There was no deviation from 
Hardy–Weinberg equilibrium in the groups of remitters and 
non-remitters. Table 1 shows these results.
We also measured the association separately for the SSRI 
group, a class of medication used by the greatest proportion 
of patients in the cohort. Results of comparison between 
remitters and non-remitters, shown in Table 2, were signifi-
cant, at p = 0.039, only when alleles were compared, but not 
genotypes (OR genotype T/T = 3.05, 95% CI: 0.83–11.22; 
OR allele T = 2.37, 95% CI: 0.82–6.86). The same as for 
all classes of medication taken together, in the SSRI group 
remission was associated with allele T.
Discussion
Previous studies presented apparently conflicting results 
for rs334558, some reporting association of neurological 
and psychiatric phenotypes, such as Parkinson’s disease, 
Alzheimer’s disease, bipolar disorder, schizophrenia, adverse 
reaction to medication tardive dyskinesia, and resistance to 
treatment in the case of MDD and bipolar disorder, with the 
activating allele T,49,51–59 while others identified allele C as 
potentially pathogenic in the case of Alzheimer’s disease and 
multiple sclerosis.60,61 Meta-analyses similarly reported either 
allele T associated with Alzheimer’s disease and MDD,62,63 
or allele C associated with schizophrenia.64











T/T 31.1 15.8 c21 = 0.082, p1 = 0.775; c
2
2 = 
0.139, p2 = 0.709
c2 = 6.022, p = 0.049
rs334558 C/T 50.3 50.0
T = 71.2 C/C 18.6 34.2
C = 28.8 T 56.3 40.8 c2 = 5.919, p = 0.015
C 43.7 59.2
AKT1
G/G 47.3 55.0 c21 = 1.384, p1 = 0.239; c
2
2 = 
3.265, p2 = 0.071
c2 = 1.366, p = 0.505
rs1130214 G/T 40.0 30.0
G = 72.2 T/T 12.7 15.0
T = 27.8 G 67.3 70.0 c2 = 0.219, p = 0.640
T 32.7 30.0
C/C 72.7 65.0 c21 = 0.539, p1 = 0.463; c
2
2 = 
0.178, p2 = 0.673
c2 = 1.150, p = 0.563
rs3730358 C/T 24.2 32.5
C = 80.8 T/T 3.0 2.5
T = 19.2 C 84.8 81.2 c2 = 0.625, p = 0.429
T 15.2 18.8
Notes: Numbers 1 and 2 in subscript represent group of remitters and group of non-remitters, respectively. *The allele frequencies are in the reference population of 198 
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The present study reports association of remission fol-
lowing pharmacological antidepressant treatment with allele 
T of rs334558, but a previous study reported that this allele 
is associated with resistance to antidepressant medication53 
and others reported association of this allele with poorer 
response to lithium treatment.54–56 In all these studies, 
contribution of other molecular factors, including different 
genetic and epigenetic backgrounds, was not taken account 
of. Treatment-resistant depression is a phenomenon far from 
being fully understood, with multiple molecular factors 
likely contributing to its development.2,65,66 Different genetic 
and epigenetic backgrounds may modulate the influence of 
rs334558 on the response to drug treatment. In particular, 
the genetic landscape in different human populations could 
explain the changing direction of association depending on 
the population studied. In fact, allele frequencies of this 
functional variant change drastically in different human 
populations: according to data in the 1000 Genomes Project, 
the frequency of allele T goes from 67.1% in populations 
with European ancestry to 5.9% in populations with Afri-
can ancestry (https://www.ncbi.nlm.nih.gov/projects/SNP/
snp_ss.cgi?ss=ss1305845106). This may mean that different 
genetic factors interact with this functional variant in differ-
ent human populations. It is thus possible that in our cohort 
a different genetic and/or epigenetic background defines the 
different outcome in the presence of allele T, namely remis-
sion following pharmacological treatment. Further examples 
of extensively investigated functional candidate genes, whose 
association with mental disorders and treatment response 
changes in different populations, are the brain-derived 
neurotrophic factor, encoded by BDNF,67 and the serotonin 
transporter, encoded by SLC6A4.68
Because drug treatment of depressive disorders, due to 
their extensive heterogeneity, seems to be better viewed from 
the standpoint of personalized medicine, it is important to 
define actionable molecular biomarkers that will help predict 
treatment response.10–19 The functional variant rs334558 could 
be such a genetic and pharmacogenetic biomarker for a num-
ber of phenotypes, including mood disorders, schizophrenia 
and neurodegenerative disorders. This biomarker could even-
tually be used in clinical settings, together with other relevant 
multidimensional data, such as levels of GSK3B’s promoter 
methylation or levels of expression of downstream targets 
of this gene, analyzed by machine-learning algorithms,69–71 
in order to determine the precise molecular etiopathologi-
cal processes and recommend the appropriate personalized 
medicine-driven treatment.27,72–75
It is important to note that the personalized medicine 
approach, in the context of treatment of depressive disorders 
in particular, will be substantially complex because the task of 
determining actionable biomarkers will require an important 
volume of functional studies referring to treatment response. 
Multiplex functional studies76 should be the most appropri-
ate way to proceed, given the substantial volume of data 
involved. In addition, personalized medicine applications in 
clinic, including pharmacogenetic testing, have not yet been 
convincingly shown to be cost-effective,73,74 so more prospec-
tive studies evaluating cost-effectiveness and development of 
new cost-effective treatment schemes are needed.
Conclusion
This study reported data, suggesting the role of the functional 
variant rs334558 as a pharmacogenetic biomarker for depres-
sive disorders in the context of personalized medicine-driven 
treatment. The results of genotyping should be used in con-
junction with other relevant biomarkers because the pheno-
typic outcome in the case of this potential biomarker depends 
on other genetic and epigenetic factors that modulate it.
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rs334558 T/T 33.7 14.3 c21 = 0.001, p1 = 0.975; 
c22 = 0.159, p2 = 0.690
c2 = 4.248, p = 0.120
C/T 48.8 52.4
C/C 17.4 33.3
T 58.1 40.5 c2 = 4.250, p = 0.039
C 41.9 59.5
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